Organogenesis Holdings (ORGO) AI Stock Analysis

• Market Cap: $503.63M
• Dividend Yield: N/A
• Average Volume (3M): 780.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: -4.21%
• EPS Growth: 7.78%
• Country: US
• Employees: 869
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.12
• Shares Outstanding: 126,857,710
• 10 Day Avg. Volume: 1,010,008
• 30 Day Avg. Volume: 780,182
• PEG Ratio: -5.91
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 0.87
• P/FCF Ratio: 100.90
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $8.00
• Price Target Upside: 96.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $4.00 ▼(-1.96% Downside)

Organogenesis Holdings' overall stock score is primarily impacted by its financial performance challenges, including declining revenue and profitability. Technical indicators suggest bearish momentum, and valuation metrics are unattractive due to a negative P/E ratio. However, the recent earnings call provided some optimism with strong revenue growth and favorable policy developments, which slightly offset the negative aspects.

Positive Factors

Revenue Growth

The significant year-over-year revenue growth indicates strong demand for Organogenesis's products, suggesting a solid market position and potential for continued expansion.

CMS Policy Favorable for Future Growth

The CMS policy change is expected to expand access for PMA products, potentially increasing sales and market penetration, which supports long-term growth.

Positive Adjusted EBITDA

The improvement in adjusted EBITDA reflects better operational efficiency and profitability, enhancing the company's financial health and sustainability.

Negative Factors

ReNu Phase III Trial Setback

The trial setback could delay product development and commercialization, impacting future revenue streams and competitive positioning in the regenerative medicine market.

Cash Position Decline

The significant decrease in cash reserves may limit the company's ability to invest in growth opportunities and manage financial obligations, affecting long-term stability.

Declining Revenue Growth

The negative revenue growth trend indicates potential challenges in maintaining market share and profitability, which could hinder long-term financial performance.

Organogenesis Holdings Business Overview & Revenue Model

Company Description

Organogenesis Holdings Inc. is a leader in regenerative medicine, specializing in the development and commercialization of innovative advanced wound care and surgical biologics. The company operates primarily in the healthcare sector, focusing on products that utilize human cellular and tissue-based therapies. Its core offerings include dermal regeneration matrices, skin substitutes, and other advanced wound care solutions aimed at improving patient outcomes in chronic and complex wounds.

How the Company Makes Money

Organogenesis generates revenue primarily through the sale of its advanced wound care and surgical biologics products. The company has established a diverse revenue model that includes direct sales to hospitals, outpatient clinics, and other healthcare providers. Key revenue streams come from product sales in the United States and internationally, supported by a strong sales force and distribution network. Additionally, Organogenesis benefits from collaborations and partnerships with healthcare institutions and payers, which enhance its market presence and facilitate access to its products. The company also invests in research and development to innovate and expand its product portfolio, contributing to long-term revenue growth through new offerings in the regenerative medicine space.

Organogenesis Holdings Financial Statement Overview

Summary

Organogenesis Holdings faces challenges with declining revenue and profitability in the TTM period, impacting its income statement and cash flow. However, the balance sheet remains strong with low leverage, providing stability. The company needs to address operational inefficiencies to improve its financial performance.

Income Statement

Organogenesis Holdings has experienced declining revenue growth, with a negative growth rate of -6.37% in the TTM period. The company also shows negative net profit and EBIT margins, indicating challenges in maintaining profitability. However, historical data shows periods of positive growth and profitability, suggesting potential for recovery.

Balance Sheet

The company's debt-to-equity ratio has improved over time, currently at a low 0.11, indicating a conservative leverage position. However, the return on equity is negative in the TTM period, reflecting recent profitability challenges. The equity ratio remains stable, suggesting a solid capital structure.

Cash Flow

Organogenesis Holdings shows a significant increase in free cash flow growth in the TTM period, but operating cash flow remains negative, indicating cash management issues. The free cash flow to net income ratio is strong, suggesting efficient cash conversion despite profitability challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	429.53M	482.04M	433.14M	450.89M	468.06M	338.30M
Gross Profit	313.68M	366.30M	326.66M	345.87M	353.86M	250.98M
EBITDA	-13.98M	15.76M	36.03M	40.32M	87.00M	37.23M
Net Income	-10.98M	861.00K	4.95M	15.53M	94.20M	17.23M
Balance Sheet
Total Assets	461.13M	497.89M	460.02M	449.36M	443.26M	294.49M
Cash, Cash Equivalents and Short-Term Investments	73.08M	135.57M	104.34M	102.48M	113.93M	84.39M
Total Debt	40.82M	43.31M	119.35M	123.79M	132.30M	84.77M
Total Liabilities	99.91M	112.57M	181.36M	183.69M	201.22M	148.41M
Stockholders Equity	361.22M	385.32M	278.66M	265.67M	242.03M	141.81M
Cash Flow
Free Cash Flow	-46.37M	4.18M	6.55M	-9.04M	30.76M	-14.34M
Operating Cash Flow	-33.18M	14.21M	30.92M	24.86M	61.98M	6.80M
Investing Cash Flow	-13.19M	-10.03M	-24.36M	-33.90M	-31.22M	-24.83M
Financing Cash Flow	29.63M	27.64M	-5.50M	-2.20M	-1.04M	42.47M

Organogenesis Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORGO, the sentiment is Positive. The current price of 4.08 is below the 20-day moving average (MA) of 4.16, below the 50-day MA of 4.43, and below the 200-day MA of 4.21, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 76.18 is Negative, neither overbought nor oversold. The STOCH value of 36.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORGO.

Organogenesis Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EBS	71 Outperform	$539.38M	7.85	13.92%	―	-29.91%	―
SIGA	71 Outperform	$582.87M	7.09	43.61%	―	3.86%	-2.60%
ESPR	53 Neutral	$680.97M	―	―	―	2.83%	13.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORGO	51 Neutral	$503.63M	―	-2.64%	―	-4.21%	7.78%
SNDL	49 Neutral	$476.19M	―	-7.82%	―	1.76%	18.31%
EOLS	46 Neutral	$440.51M	―	―	―	15.10%	0.18%

Organogenesis Holdings Corporate Events

Organogenesis Holdings Reports Record Revenue, Raises Guidance

Organogenesis Holdings Inc. is a prominent player in the regenerative medicine sector, focusing on advanced wound care and surgical and sports medicine markets, offering a diverse range of innovative products.

Organogenesis Holdings’ New Study on Diabetic Foot Ulcers: A Potential Game-Changer?

Study Overview: Organogenesis Holdings is conducting a study titled A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Assessing the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers. The study aims to evaluate the effectiveness of a new treatment for chronic diabetic foot ulcers, a significant health issue affecting many individuals with diabetes.

Organogenesis Holdings Faces Setback in ReNu Phase 3 Trial

On September 25, 2025, Organogenesis Holdings announced that its second Phase 3 trial of ReNu, a cryopreserved amniotic suspension allograft for knee osteoarthritis, did not achieve statistical significance for its primary endpoint. Despite this, the trial showed a numerical improvement in baseline pain reduction and maintained a favorable safety profile. The company plans to request a pre-Biologics License Application meeting with the FDA to discuss using combined data from both Phase 3 studies to support a BLA approval, emphasizing ReNu’s potential to address unmet medical needs in knee osteoarthritis.

The most recent analyst rating on (ORGO) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Organogenesis Holdings stock, see the ORGO Stock Forecast page.

Organogenesis Holdings’ Earnings Call: Mixed Sentiments and Strategic Moves

The latest earnings call for Organogenesis Holdings painted a mixed picture, with significant achievements in certain segments being overshadowed by declines in others. While the company reported growth in its Surgical & Sports Medicine segment and progress in strategic initiatives and CMS payment reforms, these positives were tempered by notable declines in Advanced Wound Care revenue, overall revenue, and profitability. The reduction in financial guidance and a decline in gross margin further contributed to a challenging outlook for the company.

Organogenesis Holdings Reports Mixed Q2 2025 Results

Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care and surgical and sports medicine markets.